Friday, 22 Jun 2018

You are here

Denosumab Increases Trabecular Bone

Bone mineral density (BMD) measurement vie DEXA scan commonly used to assess bone density and fracture risk in postmenopausal osteoporosis provides us with approximate assessment of bone health while lacking sensitivity in vertebral fracture risk prediction. Newer techniques, such as the trabecular bone score (TBS), provide better insight into bone microarchitecture - an important factor for fragility fracture.

TBS has been shown to be predictive of fragility fractures in postmenopausal women with primary osteoporosis and has been newly included in international guidelines, providing an additional screening tool to identify patients in need of therapeutic intervention.

Assuming TBS may have a better predictive value in future fracture preventions, this retrospective review of the 3 –year long FREEDOM trial was designed to explore the effect of denosumab on TBS and association between TBS and BMD in 7808 postmenopausal women with osteoporosis in FREEDOM cohort.

Using TBS iNsight software in a blinded-to-treatment manner, the TBS of subjects who participated in the DXA substudy was determined retrospectively. 285 patients were established to have measurable TBS at baseline and were included in analysis.

In the denosumab group, progressive statistically significant increase from baseline at 12/24/26 months was observed for both BMD (5.7/7.8/ 9.8%, respectively) and TBS (1.4/1.9/ 2.4%), p value p<0.001.

More subjects in the denosumab group than in the placebo group had TBS gains of 5.82% or greater at 12 months (15 vs 11%; p = 0.271), 24 months (21 vs 9%; p = 0.012), and 36 months (20 vs 6%; p = 0.001).

There was no significant correlation between TBS and BMD in this study, which in author’s opinion supports the principle that TBS provides a measure of bone not captured by standard densitometric techniques and may allow for an improved assessment of differences in responses to diverse therapies for osteoporosis.

The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

I would encourage the title of this segment to be that Denosumab increases Trabecular Bone Score. No anti-resorptive can actually increase bone mass. BMD and in a complex way TBS assesses bone mineral and in the case of TBS, the pattern of distribution. Anti-resorptive drugs decrease bone remodeling and more mineral goes into the stable bone mass. More mineral may alter the BMC and also the edge detection of the interface between bone and soft tissue. Clearly BMD and TBS can increase but bone mass does not increase. I urge readers to look at paired biopsy studies.

More Like This

Update on Osteoporosis

This session was an update on the management of osteoporosis given by Professor Christian Roux from France.

He emphasised the use of composite risk score like the FRAX. He highlighted that the risk of vertebral fracture is increased by both the recency and severity of previous vertebral fracture. So it is important that those with vertebral fractures are followed up and treated appropriately to prevent subsequent fractures.

Restless Sleep and Inactivity Intertwined in OA

Adults with osteoarthritis (OA) of the knee who frequently experienced restless sleep were less likely to engage in potentially beneficial moderate-to-vigorous physical activity, analysis of data from the Osteoarthritis Initiative found.

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Bisphosphonate Drug Holidays May Result in Fractures

A report in Endocrine Practice shows that drug holidays from bisphosphonates results in a 15% risk of fractures.  (Citation source:

USPSTF Recommendations on Vitamin D, Calcium Supplementation to Prevent Fractures

The U.S. Preventive Services Task Force (USPSTF) concludes current scientific evidence is insufficient regarding the use of vitamin D and calcium, alone or in combination, to prevent fractures in men and premenopausal women. The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in postmenopausal women. Current scientific evidence is insufficient regarding the use of vitamin D and calcium at doses greater than 400 IU of vitamin D and greater than 1,000 mg of calcium in postmenopausal women.